Gerd Bendas
Prof. Dr. Gerd Bendas
  • Pharmazeutisches Institut
  • chemoresistance
  • heparin
  • platelets
The Bendas group is active in an oncological basic research, focussing cell biological approaches to identify molecular mechanisms of chemoresistance of tumor cells to obtain novel targets for sensitization strategies. Furthermore, we investigate the impact of the microenvironment of tumors on metastatic capacities, mainly the role of platelets in a hematogenous thrombogenic context or for shifting the immune system. Glycosaminoglycans, heparin or their synthetic mimetics were central for these approaches.
Ausgewählte Publikationen

Lopez V, Schuh HJM, Mirza S, Vaaßen VJ, Schmidt MS, Sylvester K, Idris RM, Renn C, Schäkel L, Pelletier J, Sévigny J, Naggi A, Scheffler B, Lee SY, Bendas G, Müller CE. (2023) Heparins are potent inhibitors of ectonucleotide pyrophosphatase/phospho-diesterase-1 (NPP1) - a promising target for the immunotherapy of cancer. Front Immunol.14:1173634.

Gockel LM, Nekipelov K, Ferro V, Bendas G, Schlesinger M. (2022) Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin.Cancer Immunol Immunother. 71:2523-2533.

Gockel LM, Heyes M, Li H, Al Nahain A, Gorzelanny C, Schlesinger M, Holdenrieder S, Li JP, Ferro V, Bendas G. (2021) Inhibition of Tumor-Host Cell Interactions Using Synthetic Heparin Mimetics. ACS Appl Mater Interfaces. 13:7080-7093.

Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G. (2020) β1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta Mol Cell Res. 1867:118663.

Gerd Bendas
Prof. Dr. Gerd Bendas
Wird geladen